ORCHESTRA BIOMED HOLDINGS INC.
NASDAQ: OBIO (Orchestra BioMed Holdings, Inc.)
Last update: 32 minutes ago6.97
-0.15 (-2.11%)
| Previous Close | 7.12 |
| Volume | 551,845 |
| Price / Sales | 14.70 |
| Price / Book | 57.25 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,179.84% |
| Diluted EPS (TTM) | -1.77 |
| Quarterly Revenue Growth (YOY) | 40.00% |
| Total Debt/Equity (MRQ) | 97.55% |
| Current Ratio (MRQ) | 3.35 |
| Operating Cash Flow (TTM) | -54.06 M |
| Levered Free Cash Flow (TTM) | -28.16 M |
| Return on Assets (TTM) | -60.70% |
| Return on Equity (TTM) | -179.12% |
News Mood
-
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
2 days ago, 7:55AM
-
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
10 Nov, 3:10PM
-
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
10 Nov, 4:40PM
-
Orchestra BioMed Announces Pricing of Public Offering
05 Nov, 9:42PM
-
Orchestra BioMed Announces Proposed Public Offering
05 Nov, 3:01PM
AIStockmoo Score
| Value 30% | -3.1 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| Timing 30% | 3.4 |
| From our AI technical analysis of the chart. info | NA |
| Uptrend over the past year. Trading near its 52-week high. info | |
| Price and its moving averages are lined up in an uptrend. Its main moving average is flat. Close to its rising moving average. Volume is heavier on up days. info | |
| Candle Patterns info | NA |
| Above its medium-term trend line. info | |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | 3.0 |
| Several insiders net buying recently. info | |
| Institutions net +5.72% of shares in their latest 13F filings: 61 holders increased, 31 decreased (quarter to 30 Sep 2026). info | |
| Short interest +11.0% from 31 Aug to 30 Oct 2026, 7 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| No clear signal from support and resistance. info | |
| Final Score | 0.53 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Orchestra BioMed Holdings, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| OBIO | - | - | - | 57.25 |
| TRML | 1 B | - | - | 4.76 |
| VRDN | - | - | - | 7.26 |
| VRCA | - | - | - | 15.60 |
| TECH | - | 0.44% | - | 5.28 |
| ABEO | - | - | - | 1.10 |
Select this tab to load the latest available analysis.
|
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 21.81% |
| % Held by Institutions | 49.62% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FAIN ERIC S | 5.70 | - | 20,000 | 114,000 |
| HOCHMAN DAVID P | 5.70 | - | 5,000 | 28,500 |
| PACITTI DAVID | 5.70 | - | 20,000 | 114,000 |
| TAYLOR ANDREW LAWRENCE | 5.70 | - | 1,000 | 5,700 |
| Aggregate Net Quantity | 46,000 | |||
| Aggregate Net Value ($) | 262,200 | |||
| Aggregate Avg. Buy ($) | 5.70 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TAYLOR ANDREW LAWRENCE | Officer | 09 Nov 2026 | Buy (+) | 1,000 | 5.70 | 5,700 |
| HOCHMAN DAVID P | Officer | 09 Nov 2026 | Buy (+) | 5,000 | 5.70 | 28,500 |
| PACITTI DAVID | Director | 09 Nov 2026 | Buy (+) | 20,000 | 5.70 | 114,000 |
| FAIN ERIC S | Director | 09 Nov 2026 | Buy (+) | 20,000 | 5.70 | 114,000 |
Institutions
Institutional ownership: 41.73%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 61 | 5,034,559 |
| Decreased | 31 | 1,386,397 |
| New | 27 | 1,437,879 |
| Sold out | 11 | 569,836 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 2,732,484 | 7.0 |
| 15 Oct 2026 | 2,552,988 | 9.7 |
| 30 Sep 2026 | 2,547,249 | 7.0 |
| 15 Sep 2026 | 2,372,557 | 6.6 |
| 31 Aug 2026 | 2,460,669 | 5.8 |
| 14 Aug 2026 | 2,383,854 | 13.1 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 16 Nov 2026 | Yahoo Finance |
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 10 Nov 2026 | Yahoo Finance |
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 10 Nov 2026 | Yahoo Finance |
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).Medtronic… |
| 05 Nov 2026 | Yahoo Finance |
Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 05 Nov 2026 | Yahoo Finance |
Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 29 Oct 2026 | Yahoo Finance |
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels… |
| 22 Oct 2026 | Yahoo Finance |
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq… |
| 20 Oct 2026 | Yahoo Finance |
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday . |
| 01 Oct 2026 | Yahoo Finance |
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing… |
| 21 Sep 2026 | Yahoo Finance |
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
| 16 Sep 2026 | Yahoo Finance |
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO)… |
| 15 Sep 2026 | Yahoo Finance |
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides… |
| 02 Sep 2026 | Yahoo Finance |
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported… |
| 27 Aug 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman… |
| 20 Aug 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |